Aspergillus fumigatus is a filamentous fungus that produces abundant pigmented conidia. Several fungal components have been identified as virulence factors, including melanin; however, the impact of these factors in a repeated exposure model resembling natural environmental exposures remains unknown. This study examined the role of fungal melanin in the stimulation of pulmonary immune responses using immunocompetent BALB/c mice in a multiple exposure model. It compared conidia from wild-type A. fumigatus to two melanin mutants of the same strain, Δarp2 (tan) or Δalb1 (white). Mass spectrometry-based analysis of conidial extracts demonstrated that there was little difference in the protein fingerprint profiles between the three strains. Field emission scanning electron microscopy demonstrated that the immunologically inert Rodlet A layer remained intact in melanin-deficient conidia. Thus, the primary difference between the strains was the extent of melanization. Histopathology indicated that each A. fumigatus strain induced lung inflammation, regardless of the extent of melanization. In mice exposed to Δalb1 conidia, an increase in airway eosinophils and a decrease in neutrophils and CD8(+) IL-17(+) (Tc17) cells were observed. Additionally, it was shown that melanin mutant conidia were more rapidly cleared from the lungs than wild-type conidia. These data suggest that the presence of fungal melanin may modulate the pulmonary immune response in a mouse model of repeated exposures to A. fumigatus conidia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604601 | PMC |
http://dx.doi.org/10.3109/1547691X.2013.819054 | DOI Listing |
Tech Innov Patient Support Radiat Oncol
March 2025
Department of Radiation Oncology, Emory University, Atlanta, GA, USA.
Background: Recent patient studies have linked higher immune cell doses with worse quality of life and survival. For thoracic radiotherapy, heart dose is a major contributor to the effective dose to immune cells (EDIC).
Purpose: This study investigates heart and immune cell doses for plans optimized using a cardiac-sparing knowledge-based planning (KBP) model and the impact of carefully crafted beam geometry.
BMJ Oncol
February 2024
NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia.
BMJ Oncol
August 2024
Cyrus Tang Medical Institute, State Key Laboratory of Radiation Medicine and Prevention, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China.
Objective: Current biomarkers for predicting immunotherapy response in non-small-cell lung cancer (NSCLC) are derived from invasive procedures with limited predictive accuracy. Thus, identifying a non-invasive predictive biomarker would improve patient stratification and precision immunotherapy.
Methods And Analysis: In this retrospective multicohort study, the discovery cohort included 205 NSCLC patients screened from ORIENT-11 and an external validation (EV) cohort included 99 real-world NSCLC patients.
BMJ Oncol
August 2024
Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
BMJ Oncol
April 2024
Deparment of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
Objective: Immune checkpoint inhibitors (ICI) that block the programmed cell death 1 (PD-1) pathway have shown promise with limited benefit. We and others have shown in small patient cohorts that an early proliferative CD8 T-cell response in the blood may be predictive of clinical response. However, these studies lack detailed analyses and comparisons between monotherapy and combination therapies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!